A phase I trial of [131I]GMIB-anti-HER2-VHH1 in healthy volunteers and BC patients demonstrated that the radiotracer was well stabilized in the circulation system and that its accumulation was not increased in the thyroid gland or stomach, as patients were treated with potassium iodide for blocking pretreatment. This evidence concerns the gene ERBB2 and breast cancer.